Document:

Exhibit 10.15

 

Addition to the Amendment
to Licensing Agreement  - Worldwide rights to

the Unit Dose Eye Product - dated November 22, 2015

 

Subject to Wize Pharma exercising
the Option mentioned in the Amendment to Licensing Agreement dated November 22, 2015 section 3, The minimal sales in every country
will be based on the formula described in the Appendix E of the Eyedrops for the USA document signed May 1, 2015, except if different
terms are agreed in advance, in writing with Resdevco.

 

Wize Pharma agrees to pay
minimum royalties for worldwide sales, beginning at the signature date as follows:

 

Year 1 - $0

Year 2 - $150,000

Year 3 - $300,000

Year 4 - $450,000

Year 5 - $600,000

Year 6 and beyond - $750,000

 

Resdevco agrees to postpone
the minimum royalty payment of 2017 for the USA ($150,000 - one hundred and fifty thousand US dollars) until March 31, 2017.

 

	Resdevco Ltd.	 	Wize Pharma Ltd.
	 	 	 
	Name: Shabtay Dikstein	 	Name: Or Eisenberg
	 	 	 
	Position: CEO	 	Position: CFO & Acting CEO
	 	 	 
	Signature:
    /s/ Prof. S.
    Dikstein                          	 	Signature:
    /s/ Or Eisenberg                               
	 	 	 
	Date: January 6, 2017	 	Date: January 5, 2017Exhibit 10.16

 

Second
Addition to the Amendment to Licensing Agreement  - Worldwide rights to the 

Unit Dose Eye Product — dated November
22, 2015

 

	1.	From
                                         the Amendment to Licensing Agreement — Worldwide rights to the Unit Dose Eye
                                         Product — signed on November 22, 2015, section 3 — Rest of the world,
                                         the first paragraph is cancelled:

 

“Resdevco
grants Wize Pharma an option to purchase all the territories which are not under a signed contract for the amount of 3 Million
USD and 0.3 UDS royalties per box of 30 unit for the dry-eye / Conjunctivochalasis product or equivalent royalties for boxes
of different quantities.”

 

	2.	Resdevco
                                         Ltd. and Wize Pharma Ltd. will keep open an option of a future discussion of purchasing
                                         the “rest of world”, under terms that will be mutually agreed upon.

 

	3.	The
                                         agreement: Addition to the Amendment to Licensing Agreement — Worldwide rights
                                         to the Unit Dose Eye Product — dated November 22, 2015, (signed on January
                                         5, 2017) is cancelled

 

	4.	The
                                         2017 minimum deductible annual royalty for the USA license: $150,000 + VAT, which was
                                         due originally on January 31, 2017, will be directly deposited in Resdevco’s account
                                         no later than May 31, 2017 at the exchange rate of 3.75 NIS per dollar.

 

	Resdevco
    Ltd.	 	Wize
    Pharma Ltd.
	 	 	 
	Name:
    Shabtay Dikstein	 	Name:
    Or Eisenberg
	 	 	 
	Position:
    CEO	 	Position:
    CEO
	 	 	 
	Signature:
    /s/ Prof. S. Dikstein	 	Signature:
    /s/ Or Eisenberg
	 	 	 
	Date:
    March 30, 2017	 	Date:
    March 30, 2017Exhibit 10.17

 

RESDEVCO
LTD.

 

 

Correction
of the Agreement dated May 1, 2015

 

We
hereby confirm our agreement to extend the time frame as outlined in our original Agreement dated May 1, 2015 and replace it with
the following section 12.5

 

“12.5)
RESDEVCO shall be entitled, at its option, to terminate this Agreement (including the License hereunder), by giving LICENSEE 30
(thirty) day written notice, if:

 

(a)
an application for marketing approval for Finished Product is not submitted to the FDA or an equivalent regulatory authority
in the Territory by four (4) years from the date of the original Agreement;

 

(b)FDA or equivalent marketing approval is not obtained for Finished Product in the Territory by six (6) years from the date of the
original Agreement. If the LICENSEE can show that the delay is not their fault an extension of one year will be granted to obtain
marketing approval;

 

(c)
Commercial sales of Finished Product shall not have commenced by three (3) months following receipt of marketing approval
for Finished Product in the Territory; or

 

(d)
Commercial sale of Finished Product having commenced, and payment under Article 7 is not timely paid by LICENSEE.”

 

Kindly
confirm your agreement to the above by countersigning

 

	 	/s/ Prof. S. Dikstein	 	/s/ Or Eisenberg
	 	Resdevco Ltd.	 	Wize Pharma Ltd.
	 	 	 	 
	 	Date: 9.6.2017	 	Date: June 16, 2017

 

 

 

 

 

 

 

 

 

P.O.B. 3338, Jerusalem, Israel

Tel. and Fax: 972-2-6524734Exhibit 10.18

 

Appendix
F to Exclusive Distribution and Licensing Agreement” between Resdevco Ltd. and Wize Pharma signed on May 1, 2015.

 

This
appendix replaces the document of the same name dated July 1, 2017

 

Article
7.2 of the “Exclusive Distribution and Licensing Agreement” between Resdevco Ltd. and Wize Pharma signed on May 1,
2015 states that “On January 1 2018 and in every January thereafter - the guaranteed minimum yearly royalty is payable,
regardless whether any type of market license was obtained or not.”

 

The
guaranteed minimum yearly royalty is defined as $475,000, as agreed.

 

Resdevco
hereby agrees that on January 1, 2018, a payment of $150,000 (one hundred and fifty thousand US dollars) + VAT will be paid by
Wize Pharma (or by any company in the name of Wize Pharma)

 

Resdevco
Ltd.. will relinquish the remainder of the payment of $325,000 (three hundred and seventy five thousand US dollars) + VAT for
the year of 2018.

 

Furthermore,
agrees that on January 1, 2019, a payment of $150,000 (one hundred and fifty thousand US dollars) + VAT will be paid by Wize Pharma
(or by any company in the name of Wize Pharma)

 

If
Wize Pharma obtains an FDA marketing license during 2019, Wize Pharma will pay Resdevco Ltd. the remainder of the payment for
2019 of $325,000 (three hundred and seventy five thousand US dollars) + VAT within thirty days of receiving the said FDA license

 

	/s/
    Prof. S Dikstein	 	/s/
    Or Eisenberg
	Resdevco
    Ltd.	 	Wize
    Pharma Ltd.
	 	 	Ocu
    Wize
	 	 	 
	Date:
    July 19, 2017	 	Date:
    July 20, 2017Exhibit 10.19

 

Appendix G. to the Exclusive Distribution and Licensing Agreement,
dated May 1, 2015

 

 

July 20, 2017

 

 

Resdevco
Ltd. hereby declares that all its patents and trade names related to the LO2A unit dose eye drops may be used by Wize Phanna Ltd./
Ocu Wize Ltd. in the territories to which the Exclusive Distribution and Licensing Agreement,
dated May 1, 2015 is extended (at present Israel and the Ukraine) as long as the contract
for those territories is valid

 

Sincerely,

 

	Wize Pharma Ltd.	 	Resdevco Ltd.
	 	 	 	 	 
	By:	/s/ Or Eisenberg	 	By:	/s/ Prof. S. Dikstein
	 	 	 	 	 
	Name:  	Or Eisenberg	 	Name:  	Prof. S. Dikstein
	 	 	 	 	 
	Title:	CFO & CEO	 	Title:	CEOExhibit 10.20

 

ASSUMPTION AGREEMENT

 

THIS ASSUMPTION AGREEMENT, dated August 30, 2016 is by
and among Resdevco Ltd., a company incorporated under the laws of the state of Israel (“Resdevco”) and
OcuWize Ltd., a company incorporated under the laws of the state of Israel (“OcuWize”).

 

WHEREAS OcuWize is a subsidiary wholly-owned by Wize Pharma Ltd. (“Wize Pharma”)
and Wize Pharma and Resdevco have entered into an Exclusive Distribution and Licensing Agreement signed on May 4, 2015, having
taken effect as of May 4, 2015, and amended several times subsequently thereafter (together with its amendments, the “Distribution
Agreement”); and

 

WHEREAS Wize Pharma wishes to transfer and assign to OcuWize all of its rights and obligations
under the Distribution Agreement in accordance with Article 13 of the Distribution Agreement (“Article 13”),
pursuant to the assignment letter dated July 13, 2016 (the “Assignment Letter” and the “Effective
Date,” respectively) attached hereto as Schedule A; and

 

WHEREAS
according to Article 13 such assignment required this Assumption Agreement; and

 

WHEREAS Resdevco hereby agrees to the
assignment as set forth in the Assignment Letter and in this Assumption Agreement;

 

NOW, THEREFORE, it is hereby acknowledged
that:

 

1.         Assignment
and Assumption. OcuWize hereby assumes all of Wize Pharma’s undertakings stipulated in the Distribution Agreement.
Any liability imposed on Wize Pharma under the Distribution Agreement shall be imposed on OcuWize as of the Effective Date. OcuWize
is obligated to fulfill the Distribution Agreement in its entirety as if OcuWize has replaced Wize Pharma’s (known there
by its former name: Star Night Technologies Ltd.) as party to the Distribution Agreement with respect to its term and conditions.
All obligations (apart from that arranged in this Assumption Agreement) will apply to OcuWize and OcuWize committed to them. All
references to “Licensee” in the Distribution Agreement will in effect refer to OcuWize;

 

2.          Miscellaneous.

 

(a)         Any
notice must be in writing and sent to the address of the party listed on the Signature Page. 

(b)         The
parties do not intend that any agency or partnership be created by this Assumption Agreement. 

(c)         This
Assumption Agreement may only be modified by a written amendment executed by an authorized representative of each party. 

(d)         Any waiver
must be explicit and in writing. No waiver by a party of a breach by another party will constitute a waiver of any different
or succeeding breach.

  

 

 

     

     

    

 

(e)         This
Assumption Agreement will be governed by and construed in accordance with the laws of the State of Israel without reference to
any principles of conflicts of law. Any dispute arising under or relating to this Assumption Agreement or any transactions contemplated
herein shall be resolved by the competent courts of Jerusalem, and each of the parties hereby submits irrevocably to the exclusive
jurisdiction of such court. 

(f)         This
Assumption Agreement (including the Assignment Letter) and the Distribution Agreement contain the entire agreement between the
parties with respect to the subject matter of this Assumption Agreement and supersede all other oral or written representations,
statements, or agreements with respect to such subject matter. 

(g)         This
Assumption Agreement hereby binds the parties and their respective heirs, successors, assignees, and personal representatives.
OcuWize may not assign this Assumption Agreement without the prior written consent of Resdevco unless such assignment complies
in accordance with Article 13. 

(h)         This Assumption Agreement may be signed in counterparts which, taken as a whole, will constitute one agreement.

 

IN WITNESS
WHEREOF, the parties have caused this Assumption Agreement to be duly executed as of the date first written above.

 

	 	Resdevco	 	Ocu Wize
	 	 	 	 
	By:	/s/ Prof. S. Dikstein	 	By:	/s/ Or Eisenberg
	Name:	Prof. S. Dikstein 	 	Name: 	Or Eisenbeng
	Title:	CEO	 	Title:	CFO & CEO

  

     

     

    

   

	Wize
    Pharma Ltd	 	 
	 	 	 
	2 Hamenofim st.
    Herzliya Pituach, P.O 12909	 
	 	 
	Tel: 072-2600536                 Fax:
    072-2600537	 

 

 

 

July
13, 2016

 

For
the attention of:

Resdevco
Ltd.

7
Habanay st.

Jerusalem

Israel

 

Dear
Sir,

 

	Re:	Assignment
    of Agreements	 

 

For
the sake of good order, we wish to inform you that in accordance with Section 13 of the Exclusive distribution and licensing agreement
signed on May 1, 2015 between Wize Pharma Ltd. (known by its former name: Star Night Technologies Ltd.) (“Wize Pharma”)
and with Resdevco Ltd. (“Resdevco”), the agreements listed in the attached Appendix A were assigned to
OcuWize Ltd., a company owned and controlled by Wize Pharma (“OcuWize”). With the exception of said assignment
no changes were made to the agreements. Furthermore, in any future agreement between us (as may be), Wize Pharma will enter into
agreements (as may be) using OcuWize.

 

Assignment
of the agreements will enter into force as of the date of this letter.

 

	 	Sincerely,
	 	 
	 	/s/
    Or Eisenberg
	 	Or Eisenberg
	 	CFO & Acting
    CEO

 

OcuWize
Ltd. Confirmation

 

We,
the undersigned, OcuWize Ltd., hereby confirm our consent to the above, and hereby accept all Wize Pharma undertakings in and
rights to the agreements listed in Appendix A.

 

	 	/s/
                                         Or Eisenberg
	 	OcuWize
Ltd.

 

     

     

    

 

Appendix
A

 

	No.	 	Date of the  Agreement*	 	Title
	1.	 	May 1, 2015	 	Exclusive distribution and licensing agreement (“Licensing Agreement”)
	2.	 	May 11, 2015	 	Appendix E of the Licensing Agreement
	3.	 	November 22, 2015	 	Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product
	4.	 	November 22, 2015	 	Amendment 1 to Licensing Agreement - Israeli Market
	5.	 	March 20, 2016	 	Amendment 2 to Licensing Agreement
	6.	 	May 31, 2016	 	Amendment 1 to Licensing Agreement - Israeli Market
	7.	 	May 31, 2016	 	Amendment 2 to Licensing Agreement - Ukraine market

 

*     
Parties to the agreements and amendments above are Wize Pharma and Resdevco.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]